Clinical disclaimer: This article is for informational purposes only and does not constitute medical advice. Never start, stop, or change medication without clinical supervision.

Key Points

  • ESSENCE used biopsy-defined MASH with fibrosis, not casual ultrasound-detected fatty liver
  • Semaglutide led to MASH resolution without worsening fibrosis in 62.9% vs 34.3% with placebo
  • Fibrosis reduction without worsening steatohepatitis occurred in 36.8% vs 22.4%
  • The evidence applies most directly to patients with biopsy-defined disease, not all fatty liver
  • Proper disease staging now matters more than ever for treatment decisions

ESSENCE matters because the fatty-liver field has suffered from too much enthusiasm and too little histology. In patients with biopsy-defined MASH and moderate or advanced fibrosis, semaglutide 2.4 mg led to resolution of steatohepatitis without worsening of fibrosis in 62.9% versus 34.3% with placebo. Reduction in liver fibrosis without worsening of steatohepatitis occurred in 36.8% versus 22.4%. [1]

Those are not trivial findings. They make semaglutide relevant to liver disease in a way earlier obesity discussions could only imply.

The trial design

This was a phase 3, randomised, placebo-controlled trial in patients with biopsy-defined MASH and fibrosis. That is important because MASH discourse often collapses into loose talk about "fatty liver" without clear disease staging. [1] Semaglutide improved both key histologic endpoints compared with placebo, meaning the drug was not merely making liver enzymes look prettier. It was changing biopsy outcomes in a significant proportion of patients.

What most articles miss

MASH is not interchangeable with casual ultrasound-detected fatty liver. ESSENCE dealt with biopsy-defined disease and fibrosis. [1] Fibrosis improvement was meaningful but not universal. This is progress, not omnipotence. Semaglutide's metabolic effects almost certainly contribute to the benefit, but the trial does not license simplistic mechanistic storytelling beyond the data.

Nor is it proof that every patient with mildly raised ALT should be moved straight to semaglutide.

What this means in practice

ESSENCE gives clinicians a more serious basis for discussing semaglutide in people with MASH and fibrosis, especially where obesity, diabetes risk, and cardiometabolic burden coexist. It also strengthens the argument for proper liver-risk interpretation. Many patients know they have "fatty liver" but have no idea whether that means benign steatosis or progressive fibrotic disease. This is exactly where evidence-led clinical interpretation matters.

When to involve your clinician

If there is known fibrosis, progressive metabolic disease, unclear alcohol contribution, or medication decisions are being made around liver risk rather than simple weight loss.

Bottom line

ESSENCE is one of the strongest pieces of evidence yet that semaglutide may have a meaningful role in serious metabolic liver disease. But the lesson is not "fatty liver is fixed." The lesson is that proper disease definition now matters even more. [1]

FAQ

What did ESSENCE show?
Semaglutide improved MASH resolution without worsening fibrosis and also improved fibrosis without worsening steatohepatitis compared with placebo. [1]
Was ESSENCE based on biopsy-proven disease?
Yes. That is one reason the trial is more important than many looser fatty-liver narratives. [1]
Does ESSENCE mean every person with fatty liver needs semaglutide?
No. The evidence applies most directly to patients with biopsy-defined MASH and fibrosis.
Why is ESSENCE important?
Because it supplied phase 3 histologic evidence, not merely biomarker enthusiasm. [1]
What is the main clinical message?
Distinguish benign steatosis from progressive fibrotic disease. The evidence now matters too much for vague labelling.

References

  1. Sanyal AJ, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025. nejm.org
  2. Wegovy (semaglutide) prescribing information. FDA. 2025.